Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Biggest Owners Are Retail Investors Who Got Richer After Stock Soared 5.1% Last Week
Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Biggest Owners Are Retail Investors Who Got Richer After Stock Soared 5.1% Last Week
Key Insights
关键见解
- Mayinglong Pharmaceutical Group's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public
- The top 16 shareholders own 50% of the company
- 21% of Mayinglong Pharmaceutical Group is held by Institutions
- 马英龙制药集团拥有大量散户投资者的所有权表明,关键决策受到广大公众股东的影响
- 前16名股东拥有公司50%的股份
- 马英龙药业集团21%的股份由机构持有
To get a sense of who is truly in control of Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993), it is important to understand the ownership structure of the business. With 44% stake, retail investors possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
要了解谁真正控制了马应龙药业集团有限公司(SHSE: 600993),了解业务的所有权结构非常重要。散户投资者持有该公司44%的股份,是公司的最大股份。换句话说,该集团将从对公司的投资中获得最多(或损失最大)。
As a result, retail investors collectively scored the highest last week as the company hit CN¥11b market cap following a 5.1% gain in the stock.
结果,散户投资者上周的总得分最高,该公司的市值在股价上涨5.1%后达到了人民币11亿元人民币。
Let's take a closer look to see what the different types of shareholders can tell us about Mayinglong Pharmaceutical Group.
让我们仔细看看不同类型的股东能告诉我们关于马英龙制药集团的哪些信息。
Check out our latest analysis for Mayinglong Pharmaceutical Group
查看我们对马英龙药业集团的最新分析
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231116/0-b71095bf75477d273967fdce7855b285-0-c42bad291679383cc261447f7ab4e63d.png/big)
What Does The Institutional Ownership Tell Us About Mayinglong Pharmaceutical Group?
机构所有权告诉我们关于马英龙药业集团的什么?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
机构在向自己的投资者报告时通常会根据基准来衡量自己,因此,一旦股票被纳入主要指数,他们通常会对股票更加热情。我们预计大多数公司都会有一些机构在册,尤其是在它们正在成长的情况下。
We can see that Mayinglong Pharmaceutical Group does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Mayinglong Pharmaceutical Group, (below). Of course, keep in mind that there are other factors to consider, too.
我们可以看到,马英龙药业集团确实有机构投资者;他们持有该公司很大一部分股票。这表明专业投资者有一定的信誉。但是我们不能仅仅依靠这个事实,因为机构有时会像每个人一样进行不良投资。如果两个大型机构投资者试图同时抛售一只股票,股价大幅下跌的情况并不少见。因此,值得一看马英龙药业集团过去的收益轨迹(见下文)。当然,请记住,还有其他因素需要考虑。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231116/0-b71095bf75477d273967fdce7855b285-1-bd8999e84058ca0086f375464cba73fe.png/big)
We note that hedge funds don't have a meaningful investment in Mayinglong Pharmaceutical Group. The company's largest shareholder is China Baoan Group Co., Ltd., with ownership of 29%. Meanwhile, the second and third largest shareholders, hold 5.2% and 3.2%, of the shares outstanding, respectively.
我们注意到,对冲基金没有对马应龙制药集团进行有意义的投资。公司的最大股东是中国宝安集团有限公司,拥有29%的股权。同时,第二和第三大股东分别持有已发行股份的5.2%和3.2%。
A closer look at our ownership figures suggests that the top 16 shareholders have a combined ownership of 50% implying that no single shareholder has a majority.
仔细观察我们的所有权数据就会发现,前16名股东的合并所有权为50%,这意味着没有一个单一股东拥有多数股东。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.
虽然研究公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向哪个方向吹来也是有意义的。据我们所知,没有分析师对该公司进行报道,因此它可能处于雷达之下。
Insider Ownership Of Mayinglong Pharmaceutical Group
马英龙药业集团的内幕所有权
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
尽管内部人士的确切定义可能是主观的,但几乎每个人都认为董事会成员是内部人士。公司管理层对董事会负责,后者应代表股东的利益。值得注意的是,有时高层管理人员自己也是董事会成员。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常认为内部所有权是一件好事。但是,在某些情况下,这使其他股东更难追究董事会对决策的责任。
We note our data does not show any board members holding shares, personally. It is unusual not to have at least some personal holdings by board members, so our data might be flawed. A good next step would be to check how much the CEO is paid.
我们注意到,我们的数据并未显示任何董事会成员个人持有股份。董事会成员不持有至少部分个人持股的情况很少见,因此我们的数据可能存在缺陷。一个不错的下一步是检查首席执行官的薪水是多少。
General Public Ownership
一般公有制
The general public-- including retail investors -- own 44% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
包括散户投资者在内的公众拥有该公司44%的股份,因此不容忽视。尽管这种所有权规模可能不足以影响有利于他们的政策决定,但它们仍然可以对公司政策产生集体影响。
Private Company Ownership
私人公司所有权
Our data indicates that Private Companies hold 6.1%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
我们的数据表明,私营公司持有公司6.1%的股份。可能值得对此进行更深入的研究。如果内部人士等关联方对其中一家私营公司感兴趣,则应在年度报告中披露。私营公司也可能在公司中拥有战略利益。
Public Company Ownership
上市公司所有权
It appears to us that public companies own 29% of Mayinglong Pharmaceutical Group. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.
在我们看来,上市公司拥有马英龙制药集团29%的股份。我们无法确定,但这很可能是战略利益。这些企业可能相似,也可能合作。
Next Steps:
后续步骤:
It's always worth thinking about the different groups who own shares in a company. But to understand Mayinglong Pharmaceutical Group better, we need to consider many other factors. To that end, you should learn about the 2 warning signs we've spotted with Mayinglong Pharmaceutical Group (including 1 which is potentially serious) .
始终值得考虑拥有公司股份的不同群体。但是,为了更好地了解马英龙药业集团,我们需要考虑许多其他因素。为此,你应该了解我们在马英龙制药集团发现的两个警告信号(包括一个可能很严重的信号)。
Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.
当然,这可能不是最值得买入的股票。因此,来看看这份免费的有趣公司名单吧。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。